Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RNAZ
TRANSCODE THERAPEUTICS, INC.
NASDAQ
$2.18
▼ DOWN 4.39% (-0.10)

KEY STATISTICS

Market Cap$2.31 M
52w High$20.99
52w Low$2.09
Dividend Yield—
Frequency—
P/E-0.04
Volume37.33K
Shares Out.1.06M

COMPANY

LEADERSHIP

Philippe Calais
CHIEF EXECUTIVE
Philippe Calais

COMPENSATION 2026

Salary$123,808
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$373,808

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 8, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
12

UPCOMING EARNINGS

DateNov 18, 2026
DayWednesday
Rev. Est.—
NOV
18
WED

SPLIT RECORD

DATETYPERATIO
2025-05-15Reverse1:28
2024-12-04Reverse1:33
2024-01-16Reverse1:40
2023-05-23Reverse1:20

PRICE

$2.18 ▼ DOWN 4.39% (−$0.10)
OVERLAYS
$2.17$2.25$2.339:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.18

About TransCode Therapeutics, Inc.

https://www.transcodetherapeutics.com ↗

TransCode Therapeutics, a Boston-based biopharma founded in 2016, develops drugs and diagnostics targeting metastatic cancer, including preclinical candidates like TTX-MC138, siRNA, CRISPR, and mRNA platforms for cancer treatment and immune activa...

INDUSTRY

Biotechnology

A PRODUCT TRANSCODE THERAPEUTICS, INC. IS KNOWN FOR

TTX-MC138
TTX-MC138

TTX-MC138 is TransCode's lead RNA-based therapeutic in Phase I/II trials, targeting microRNA-10b to inhibit metastatic progression in cancers and address a major cause of cancer-related mortality.

COMPETITORS

COMPETITOR
ALNY COMPARE
ARWR COMPARE
IONS COMPARE
PHIO COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 6.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
2.63%
HOLDERS
7
TOP 7 OF 7 · RANKED BY POSITION SIZE
Geode Capital Management, LLC
12.7K sh · $109.69K
Ubs Group AG
8.3K sh · $71.42K
Act Capital Management, LLC
6.5K sh · $7K
Tower Research Capital LLC (Trc)
228 sh · $1.96K
Wells Fargo & Company/Mn
55 sh · $474
Sbi Securities Co., Ltd.
12 sh · $103
Royal Bank Of Canada
8 sh · $0

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

★
10 PERCENT OWNER
DEFJ, LLC
— · —
2026-07-27
★
10 PERCENT OWNER
DEFJ, LLC
— · 11.8M shares
2026-07-27
★
10 PERCENT OWNER
DEFJ, LLC
— · 2.0M shares
2026-07-27
★
10 PERCENT OWNER
DEFJ, LLC
Sale · 1.2K shares
2026-08-03

SECTORS PEERS

PEERPRICE
PHIO$1.13COMPARE
KPRX$2.62COMPARE
APRE$0.84COMPARE
INAB$1.03COMPARE
BOLT$3.81COMPARE
ACXP$1.44COMPARE
APVO$2.37COMPARE
HCWB$3.43COMPARE